The Prostaglandin E2 Receptor EP4 Subtype pipeline drugs market research report outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Prostaglandin E2 Receptor EP4 Subtype pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Oncology, Immunology, Musculoskeletal Disorders, and Central Nervous System which include the indications Colorectal Cancer, Solid Tumor, Autoimmune Disorders, Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Pain, and Cancer Pain. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype targeted therapeutics development with respective active and dormant or discontinued products.

The Prostaglandin E2 Receptor EP4 Subtype pipeline targets constitutes close to 23 molecules. Out of which, approximately 22 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 5, 6, 1, and 10 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Prostaglandin E2 Receptor EP4 Subtype overview

Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

For a complete picture of Prostaglandin E2 Receptor EP4 Subtype’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.